Literature DB >> 22538098

Calcipotriol delivery into the skin with PEGylated liposomes.

Nina Østergaard Knudsen1, Stine Rønholt, Ragnhild Djønne Salte, Lene Jorgensen, Thorsten Thormann, Line Hollesen Basse, Jens Hansen, Sven Frokjaer, Camilla Foged.   

Abstract

The D-vitamin analogue calcipotriol is commonly used for topical treatment of psoriasis, but skin penetration is required for calcipotriol to reach its pharmacological target: the keratinocytes in the lower epidermis. Liposomes can enhance the delivery of drugs into the skin, but a major challenge for the development of dosage forms containing liposomes is to maintain the colloidal stability in the formulation. The purpose of this study was to investigate the effect of stabilising liposomes with the lipopolymer poly(ethylene glycol)-distearoylphosphoethanolamine (PEG-DSPE) on the physicochemical properties of the liposomes and the ability to deliver membrane-intercalated calcipotriol into the skin. Inclusion of 0.5, l and 5 mol% PEG-DSPE in the membrane enhanced the colloidal stability of the liposomes without compromising the delivery of calcipotriol from the vehicle into excised pig skin. Calcipotriol-loaded liposomes with 1 mol% PEG-DSPE did even provide for a significantly increased deposition of calcipotriol into the stratum corneum. The size of the liposomes affected the penetration of calcipotriol into the stratum corneum since small unilamellar vesicles enhanced calcipotriol penetration as compared to large multilamellar vesicles, indicating that the liposomes to some extent migrate as intact vesicles into the stratum corneum. However, calcipotriol penetrated the skin better than the lipid component of the liposomes, suggesting that at least a fraction of the drug is released from the liposomes during skin migration. In conclusion, PEGylation is therefore a promising approach for stabilising calcipotriol-containing liposomal dispersions without compromising their favourable skin accumulation properties.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22538098     DOI: 10.1016/j.ejpb.2012.04.005

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  10 in total

Review 1.  Human skin models: From healthy to disease-mimetic systems; characteristics and applications.

Authors:  Tânia Moniz; Sofia A Costa Lima; Salette Reis
Journal:  Br J Pharmacol       Date:  2020-08-19       Impact factor: 8.739

2.  PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability, bioavailability, antitumor efficacy, and toxicity.

Authors:  Yang Liu; Bin Xie; Lin Li; Xinyu Zhang; Yu Zhang; Haibing He; Tian Yin; Xing Tang; Cuifang Cai; Jingxin Gou
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 3.  Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis.

Authors:  Sujata Pralhad Sawarkar; Vijay Yadav
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

Review 4.  Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis.

Authors:  Prativa Biswasroy; Deepak Pradhan; Biswakanth Kar; Goutam Ghosh; Goutam Rath
Journal:  AAPS PharmSciTech       Date:  2021-05-26       Impact factor: 3.246

5.  Calcipotriol delivery into the skin as emulgel for effective permeation.

Authors:  V Naga Sravan Kumar Varma; P V Maheshwari; M Navya; Sharath Chandra Reddy; H G Shivakumar; D V Gowda
Journal:  Saudi Pharm J       Date:  2014-02-25       Impact factor: 4.330

Review 6.  Progress in Psoriasis Therapy via Novel Drug Delivery Systems.

Authors:  Nitha Vincent; Devi D Ramya; Hari Bn Vedha
Journal:  Dermatol Reports       Date:  2014-09-08

7.  Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation.

Authors:  Rofida Albash; Aly A Abdelbary; Hanan Refai; Mohamed A El-Nabarawi
Journal:  Int J Nanomedicine       Date:  2019-03-15

8.  Design and development of topical liposomal formulations in a regulatory perspective.

Authors:  Michele Schlich; Umberto M Musazzi; Virginia Campani; Marco Biondi; Silvia Franzé; Francesco Lai; Giuseppe De Rosa; Chiara Sinico; Francesco Cilurzo
Journal:  Drug Deliv Transl Res       Date:  2021-11-09       Impact factor: 5.671

Review 9.  Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs.

Authors:  Ana M Martins; Andreia Ascenso; Helena Margarida Ribeiro; Joana Marto
Journal:  Mol Neurobiol       Date:  2020-02-15       Impact factor: 5.590

Review 10.  Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.

Authors:  Salma A Fereig; Ghada M El-Zaafarany; Mona G Arafa; Mona M A Abdel-Mottaleb
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.